FIELD: medicine, pharmaceutics.
SUBSTANCE: there is offered application of dipeptidylpeptidase IV inhibitor (DPP-IV inhibitor), preferentially (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyanopyrrolidine or its pharmaceutically acceptable salt, for treatment of cardiovascular diseases or injures, renal diseases or damages, cardiac insufficiency or related diseases, related method and pharmaceutical composition of the same purpose.
EFFECT: compound reduces both hypertrophy of blood vessel wall and aortic ventricle, causes endothelium mediated increase of vasorelaxation, and risk of hypostasis in prolonged application in comparison with other DPPs-IV.
26 cl, 4 ex
